Patient-reported outcomes with insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial
| dc.contributor.author | Jódar Gimeno, José Esteban | |
| dc.contributor.author | Doshi, Ankur | |
| dc.contributor.author | Gouet, D. | |
| dc.contributor.author | Oviedo, A. | |
| dc.contributor.author | Rodbard, H.W. | |
| dc.contributor.author | Tentolouris, Nikolaos | |
| dc.contributor.author | Busk, A.K. | |
| dc.contributor.author | Basse, A. | |
| dc.contributor.author | Billings, Liana K. | |
| dc.date.accessioned | 2018-04-16T08:27:32Z | |
| dc.date.available | 2018-04-16T08:27:32Z | |
| dc.date.issued | 2017 | |
| dc.description.filiation | UEM | spa |
| dc.description.impact | No data (2017) | spa |
| dc.description.sponsorship | Novo Nordisk A/S | spa |
| dc.identifier.citation | Jódar Gimeno, E., Doshi, A., Gouet, D., Oviedo, A., Rodbard, H.W., Tentolouris, N., Busk, A.K., Basse, A., & Billings, L.K. (2017). Patient-reported outcomes with insulin degludec/liraglutide (IDegLira) vs basal-bolustherapy in patients with type 2 diabetes: DUAL VII trial. Trabajo presentado en la 53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD). | spa |
| dc.identifier.uri | http://hdl.handle.net/11268/7224 | |
| dc.language.iso | eng | spa |
| dc.peerreviewed | Si | spa |
| dc.rights.accessRights | restricted access | spa |
| dc.subject.uem | Diabetes tipo 2 | spa |
| dc.subject.uem | Insulina | spa |
| dc.subject.unesco | Sistema endocrino | spa |
| dc.subject.unesco | Tratamiento médico | spa |
| dc.title | Patient-reported outcomes with insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial | spa |
| dc.type | conference output | spa |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 3b2bb27c-56d4-4094-87ab-73ae34ec6089 | |
| relation.isAuthorOfPublication.latestForDiscovery | 3b2bb27c-56d4-4094-87ab-73ae34ec6089 |